Skip to content

Analysis of curative effect of Liraglutide monotherapy, Metformin monotherapy and Liraglutide plus Metformin dual therapy in patients with type 2 diabetes mellitus complicated with coronary artery disease

Liraglutide and Metformin treatment effects for type II diabetes

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008578
Enrollment
Unknown
Registered
2016-06-01
Start date
2012-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus complicated with coronary artery disease

Interventions

3: high dose Liraglutide
4: low dose Liraglutide plus Metformin

Sponsors

Tianjin First Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: This study was conducted from April 2012 to September 2013 at the Department of Endocrinology. Both outpatients and inpatients were included. Eligible trial patients were men and women, were previously diagnosed with T2DM, according to diagnostic and classification criteria issued by American Diabetes Association in 2005 and Clinical Practice Guidelines by European Society of Cardiology in 2006.

Exclusion criteria

Exclusion criteria: (1) Type I diabetes or other type of diabetes; (2) Preanancy, breeding and women plan to be pregnant; (3) Chronic renal dysfunction ( serum creatinine >150umol/L), liver dysfunction (The upper limit of the normal value of alanine aminotransferase and aspartate aminotransferase >2.5 times); (4) Previous episodes of acute, chronic pancreatitis; (5) With a history of cancer and a variety of other serious diseases, doctors think it should not be selected.

Design outcomes

Primary

MeasureTime frame
blood pressure;Blood glucose;glycosylated hemoglobin;body mass index;triglyceride;total cholesterol;low-density lipoprotein cholesterol;C reactive protein;left ventricular end-diastolic diameter;ejection fraction;E/A level;

Countries

China

Contacts

Public ContactYing Liu

Department of Endocrinology, Tianjin First Center Hospital

liuyingchristing@163.com+86 13920579655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026